JPM starts bioMérieux at 'neutral', says growth prospects priced in

Biomerieux SA

27/08/2025 08:35

** J.P. Morgan initiates coverage of bioMérieux BIOX.PA with a "neutral" rating, saying the company's strengths and growth prospects are already priced in the stock

      ** BioMérieux is a "fundamentally good business with exposure to attractive growth markets" especially in molecular biology, which now makes up 41% of sales and has grown at an average 23% per year over the last decade, JPM says

      ** The broker expects the French in-vitro diagnostics group's molecular segment, strong market positions, and high R&D spending to drive sales and profit growth, with margins expected to reach nearly 20% by 2028

     ** It prefers bioMérieux to peer Diasorin DIAS.MI, within the In Vitro Diagnostics sector, citing better fundamentals and earnings profile

     ** However, J.P. Morgan sees limited near-term reasons for the shares, which have risen 15% year-to-date, to rise further, as they trade at a premium to the medtech sector

 ** JPM sets a price target at 120.50 euros

     ** Out of 14 analysts that cover bioMérieux, eight rate it "strong buy" or "buy,"​five rate "hold" - LSEG data

 (Reporting by Jérôme Terroy)

 ((jerome.terroy@thomsonreuters.com))